LLY · News · 20261102N

Product Pipeline - Lp(a)

ELI LILLY & Co · 2026-11-02 · Importance 20 · Surprise 24

The reported failure of Novartis’s experimental drug pelacarsen to reduce heart attack and stroke risk despite lowering Lp(a) levels raised questions about whether targeting Lp(a) can improve clinical outcomes. The report says Lilly, along with Amgen, is developing Lp(a)-lowering drugs, with results anticipated in the coming years. The competitor result introduces uncertainty around the evidence and market prospects for Lilly’s Lp(a) pipeline.

Key facts